Delaware | 001-40208 | 82-2060643 | ||||||||||||
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||||||||
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Common stock, par value $0.001 per share | HAYW | New York Stock Exchange |
Item 2.02 | Results of Operations and Financial Condition. |
Item 9.01 | Financial Statements and Exhibits |
Exhibit No. | Description | |||||||
Press Release of the Company, dated October 29, 2024 |
||||||||
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
HAYWARD HOLDINGS, INC. | ||||||||
Date: October 29, 2024 |
By: | /s/ Eifion Jones | ||||||
Eifion Jones | ||||||||
Senior Vice President and Chief Financial Officer |
September 28, 2024 | December 31, 2023 | |||||||||||||
Assets | ||||||||||||||
Current assets | ||||||||||||||
Cash and cash equivalents | $ | 274,184 | $ | 178,097 | ||||||||||
Short-term investments | — | 25,000 | ||||||||||||
Accounts receivable, net of allowances of $2,881 and $2,870, respectively |
99,932 | 270,875 | ||||||||||||
Inventories, net | 229,363 | 215,180 | ||||||||||||
Prepaid expenses | 15,541 | 14,331 | ||||||||||||
Income tax receivable | 11,634 | 9,994 | ||||||||||||
Other current assets | 18,898 | 11,264 | ||||||||||||
Total current assets | 649,552 | 724,741 | ||||||||||||
Property, plant, and equipment, net of accumulated depreciation of $108,726 and $95,917, respectively |
164,654 | 158,979 | ||||||||||||
Goodwill | 953,175 | 935,013 | ||||||||||||
Trademark | 736,000 | 736,000 | ||||||||||||
Customer relationships, net | 209,836 | 206,308 | ||||||||||||
Other intangibles, net | 92,479 | 94,082 | ||||||||||||
Other non-current assets | 84,168 | 91,161 | ||||||||||||
Total assets | $ | 2,889,864 | $ | 2,946,284 | ||||||||||
Liabilities and Stockholders’ Equity |
||||||||||||||
Current liabilities | ||||||||||||||
Current portion of long-term debt | $ | 14,079 | $ | 15,088 | ||||||||||
Accounts payable | 73,562 | 68,943 | ||||||||||||
Accrued expenses and other liabilities | 159,709 | 155,543 | ||||||||||||
Income taxes payable | 825 | 109 | ||||||||||||
Total current liabilities | 248,175 | 239,683 | ||||||||||||
Long-term debt, net | 959,906 | 1,079,280 | ||||||||||||
Deferred tax liabilities, net | 239,362 | 248,967 | ||||||||||||
Other non-current liabilities | 69,266 | 66,896 | ||||||||||||
Total liabilities | 1,516,709 | 1,634,826 | ||||||||||||
Stockholders’ equity |
||||||||||||||
Preferred stock, $0.001 par value, 100,000,000 authorized, no shares issued or outstanding as of September 28, 2024 and December 31, 2023 |
— | — | ||||||||||||
Common stock $0.001 par value, 750,000,000 authorized; 244,078,929 issued and 215,412,560 outstanding at September 28, 2024; 242,832,045 issued and 214,165,676 outstanding at December 31, 2023 |
244 | 243 | ||||||||||||
Additional paid-in capital | 1,089,782 | 1,080,894 | ||||||||||||
Common stock in treasury; 28,666,369 and 28,666,369 at September 28, 2024 and December 31, 2023, respectively |
(358,125) | (357,755) | ||||||||||||
Retained earnings | 644,831 | 580,909 | ||||||||||||
Accumulated other comprehensive income | (3,577) | 7,167 | ||||||||||||
Total stockholders’ equity |
1,373,155 | 1,311,458 | ||||||||||||
Total liabilities, redeemable stock, and stockholders’ equity |
$ | 2,889,864 | $ | 2,946,284 |
Three Months Ended | Nine Months Ended | |||||||||||||||||||||||||
September 28, 2024 | September 30, 2023 | September 28, 2024 | September 30, 2023 | |||||||||||||||||||||||
Net sales | $ | 227,569 | $ | 220,304 | $ | 724,531 | $ | 713,983 | ||||||||||||||||||
Cost of sales | 114,474 | 114,893 | 361,770 | 374,171 | ||||||||||||||||||||||
Gross profit | 113,095 | 105,411 | 362,761 | 339,812 | ||||||||||||||||||||||
Selling, general and administrative expense | 64,509 | 59,454 | 187,678 | 172,057 | ||||||||||||||||||||||
Research, development and engineering expense | 6,449 | 6,177 | 18,870 | 19,027 | ||||||||||||||||||||||
Acquisition and restructuring related expense | 1,145 | 3,348 | 2,488 | 6,220 | ||||||||||||||||||||||
Amortization of intangible assets | 7,576 | 7,523 | 21,425 | 22,777 | ||||||||||||||||||||||
Operating income | 33,416 | 28,909 | 132,300 | 119,731 | ||||||||||||||||||||||
Interest expense, net | 13,209 | 17,448 | 48,600 | 55,939 | ||||||||||||||||||||||
Loss on debt extinguishment | — | — | 4,926 | — | ||||||||||||||||||||||
Other (income) expense, net | (705) | 1,932 | (1,989) | 1,798 | ||||||||||||||||||||||
Total other expense | 12,504 | 19,380 | 51,537 | 57,737 | ||||||||||||||||||||||
Income from operations before income taxes | 20,912 | 9,529 | 80,763 | 61,994 | ||||||||||||||||||||||
Provision (benefit) for income taxes | 4,411 | (2,259) | 16,841 | 12,343 | ||||||||||||||||||||||
Net income | $ | 16,501 | $ | 11,788 | $ | 63,922 | $ | 49,651 | ||||||||||||||||||
Earnings per share | ||||||||||||||||||||||||||
Basic | $ | 0.08 | $ | 0.06 | $ | 0.30 | $ | 0.23 | ||||||||||||||||||
Diluted | $ | 0.07 | $ | 0.05 | $ | 0.29 | $ | 0.23 | ||||||||||||||||||
Weighted average common shares outstanding | ||||||||||||||||||||||||||
Basic | 215,231,886 | 213,416,502 | 214,836,643 | 212,933,763 | ||||||||||||||||||||||
Diluted | 221,436,206 | 220,863,228 | 221,251,355 | 220,634,232 |
Hayward Holdings, Inc.
Unaudited Condensed Consolidated Statements of Cash Flows
(In thousands)
|
Nine Months Ended | |||||||||||||
September 28, 2024 | September 30, 2023 | |||||||||||||
Cash flows from operating activities | ||||||||||||||
Net income | $ | 63,922 | $ | 49,651 | ||||||||||
Adjustments to reconcile net income to net cash provided by operating activities | ||||||||||||||
Depreciation | 13,929 | 13,018 | ||||||||||||
Amortization of intangible assets | 26,299 | 27,803 | ||||||||||||
Amortization of deferred debt issuance fees | 3,248 | 3,458 | ||||||||||||
Stock-based compensation | 7,299 | 6,701 | ||||||||||||
Deferred income taxes | (8,344) | (5,965) | ||||||||||||
Allowance for bad debts | (62) | (906) | ||||||||||||
Loss on debt extinguishment | 4,926 | — | ||||||||||||
(Gain) loss on sale of property, plant and equipment | (451) | 945 | ||||||||||||
Changes in operating assets and liabilities | ||||||||||||||
Accounts receivable | 173,400 | 85,216 | ||||||||||||
Inventories | (4,204) | 61,715 | ||||||||||||
Other current and non-current assets | (6,203) | 9,500 | ||||||||||||
Accounts payable | 2,871 | (6,265) | ||||||||||||
Accrued expenses and other liabilities | (868) | (27,934) | ||||||||||||
Net cash provided by operating activities | 275,762 | 216,937 | ||||||||||||
Cash flows from investing activities | ||||||||||||||
Purchases of property, plant, and equipment | (17,552) | (22,623) | ||||||||||||
Acquisitions, net of cash acquired | (61,636) | — | ||||||||||||
Proceeds from sale of property, plant, and equipment | 311 | 13 | ||||||||||||
Proceeds from short-term investments | 25,000 | — | ||||||||||||
Net cash used in investing activities | (53,877) | (22,610) | ||||||||||||
Cash flows from financing activities | ||||||||||||||
Proceeds from revolving credit facility | — | 144,100 | ||||||||||||
Payments on revolving credit facility | — | (144,100) | ||||||||||||
Proceeds from issuance of long-term debt | 2,886 | 3,320 | ||||||||||||
Payments of long-term debt | (129,971) | (9,325) | ||||||||||||
Proceeds from issuance of short-term notes payable | 6,340 | 6,130 | ||||||||||||
Payments of short-term notes payable | (4,676) | (5,174) | ||||||||||||
Other, net | (427) | (149) | ||||||||||||
Net cash used in financing activities | (125,848) | (5,198) | ||||||||||||
Effect of exchange rate changes on cash and cash equivalents | 50 | (1,061) | ||||||||||||
Change in cash and cash equivalents | 96,087 | 188,068 | ||||||||||||
Cash and cash equivalents, beginning of period | 178,097 | 56,177 | ||||||||||||
Cash and cash equivalents, end of period | $ | 274,184 | $ | 244,245 | ||||||||||
Supplemental disclosures of cash flow information | ||||||||||||||
Cash paid-interest | $ | 47,965 | $ | 56,438 | ||||||||||
Cash paid-income taxes | 26,853 | 14,913 | ||||||||||||
Equipment financed under finance leases | 843 | — |
(Dollars in thousands) | Three Months Ended | Nine Months Ended | ||||||||||||||||||||||||
September 28, 2024 | September 30, 2023 | September 28, 2024 | September 30, 2023 | |||||||||||||||||||||||
Net income | $ | 16,501 | $ | 11,788 | $ | 63,922 | $ | 49,651 | ||||||||||||||||||
Depreciation | 4,862 | 4,428 | 13,929 | 13,018 | ||||||||||||||||||||||
Amortization | 9,253 | 9,260 | 26,299 | 27,803 | ||||||||||||||||||||||
Interest expense, net | 13,209 | 17,448 | 48,600 | 55,939 | ||||||||||||||||||||||
Income taxes | 4,411 | (2,259) | 16,841 | 12,343 | ||||||||||||||||||||||
Loss on debt extinguishment | — | — | 4,926 | — | ||||||||||||||||||||||
EBITDA | 48,236 | 40,665 | 174,517 | 158,754 | ||||||||||||||||||||||
Stock-based compensation (a) |
136 | 269 | 556 | 1,001 | ||||||||||||||||||||||
Currency exchange items (b) |
(344) | 145 | (470) | 1,276 | ||||||||||||||||||||||
Acquisition and restructuring related expense, net (c) |
1,145 | 3,348 | 2,488 | 6,220 | ||||||||||||||||||||||
Other (d) |
1,920 | 2,784 | 1,657 | 4,367 | ||||||||||||||||||||||
Total Adjustments | 2,857 | 6,546 | 4,231 | 12,864 | ||||||||||||||||||||||
Adjusted EBITDA | $ | 51,093 | $ | 47,211 | $ | 178,748 | $ | 171,618 | ||||||||||||||||||
Net income margin | 7.3 | % | 5.4 | % | 8.8 | % | 7.0 | % | ||||||||||||||||||
Adjusted EBITDA margin | 22.5 | % | 21.4 | % | 24.7 | % | 24.0 | % |
(a) | Represents non-cash stock-based compensation expense related to equity awards issued to management, employees, and directors. The adjustment includes only expense related to awards issued under the 2017 Equity Incentive Plan, which were awards granted prior to the effective date of Hayward’s initial public offering (the “IPO”). |
|||||||
(b) | Represents unrealized non-cash (gains) losses on foreign denominated monetary assets and liabilities and foreign currency contracts. |
|||||||
(c) |
Adjustments in the three months ended September 28, 2024 are primarily driven by $0.7 million of transaction and integration costs associated with the acquisition of the ChlorKing business and $0.4 million of costs to finalize actions initiated in prior years. Adjustments in the three months ended September 30, 2023 are primarily driven by $1.9 million of separation costs associated with the centralization and consolidation of operations in Europe and $1.5 million of costs associated with the relocation of the corporate headquarters.
Adjustments in the nine months ended September 28, 2024 are primarily driven by $1.3 million of transaction and integration costs associated with the acquisition of ChlorKing, $0.7 million of separation and other costs associated with the centralization and consolidation of operations in Europe and $0.4 million of costs to finalize actions initiated in prior years. Adjustments in the nine months ended September 30, 2023 are primarily driven by $2.1 million of costs associated with the relocation of the corporate headquarters, $1.9 million of separation costs associated with the centralization and consolidation of operations in Europe, $1.3 million of separation costs associated with the enterprise cost-reduction program initiated in 2022 and $0.8 million of integration costs from prior acquisitions.
|
|||||||
(d) |
Adjustments in the three months ended September 28, 2024 are primarily driven by a $1.6 million non-cash increase in cost of goods sold resulting from the fair value inventory step-up adjustment recognized as part of the purchase accounting for the acquisition of the ChlorKing business and $0.3 million of costs incurred related to litigation. Adjustments in the three months ended September 30, 2023 primarily include $1.9 million of costs related to inventory and fixed assets as part of the centralization and consolidation of operations in Europe and $0.8 million of costs incurred related to the selling stockholder offerings of shares during 2023, which are reported in SG&A in the unaudited condensed consolidated statement of operations
Adjustments in the nine months ended September 28, 2024 are primarily driven by a $1.6 million non-cash increase in cost of goods sold resulting from the fair value inventory step-up adjustment recognized as part of the purchase accounting for the acquisition of the ChlorKing business and $0.5 million of costs incurred related to litigation, partially offset by $0.5 million of gains on the sale of assets. Adjustments in the nine months ended September 30, 2023 primarily includes $1.9 million of costs related to inventory and fixed assets as part of the centralization of operations in Europe, $1.5 million of costs associated with follow-on equity offerings, $0.4 million of transitional expenses incurred to enable go-forward public company regulatory compliance and other miscellaneous items the Company believes are not representative of its ongoing business operations.
|
(Dollars in thousands) | Last Twelve Months(e) |
Fiscal Year | ||||||||||||
September 28, 2024 | December 31, 2023 | |||||||||||||
Net income | $ | 94,958 | $ | 80,687 | ||||||||||
Depreciation | 16,894 | 15,983 | ||||||||||||
Amortization | 35,575 | 37,079 | ||||||||||||
Interest expense, net | 66,245 | 73,584 | ||||||||||||
Income taxes | 24,898 | 20,400 | ||||||||||||
Loss on debt extinguishment | 4,926 | — | ||||||||||||
EBITDA | 243,496 | 227,733 | ||||||||||||
Stock-based compensation (a) |
825 | 1,270 | ||||||||||||
Currency exchange items (b) |
(960) | 786 | ||||||||||||
Acquisition and restructuring related expense, net (c) |
9,481 | 13,213 | ||||||||||||
Other (d) |
1,561 | 4,271 | ||||||||||||
Total Adjustments | 10,907 | 19,540 | ||||||||||||
Adjusted EBITDA | $ | 254,403 | $ | 247,273 | ||||||||||
Net income margin | 9.5 | % | 8.1 | % | ||||||||||
Adjusted EBITDA margin | 25.4 | % | 24.9 | % |
(a) | Represents non-cash stock-based compensation expense related to equity awards issued to management, employees, and directors. The adjustment includes only expense related to awards issued under the 2017 Equity Incentive Plan, which were awards granted prior to the effective date of the IPO. |
|||||||
(b) | Represents unrealized non-cash (gains) losses on foreign denominated monetary assets and liabilities and foreign currency contracts. |
|||||||
(c) |
Adjustments in the last twelve months ended September 28, 2024 primarily include $6.7 million of costs related to the discontinuation of a product line leading to an impairment of the associated fixed assets, inventory and intangible assets, $1.3 million of transaction and integration costs associated with the acquisition of ChlorKing, $1.2 million related to programs to centralize and consolidate operations and professional services in Europe and $0.3 million of costs to finalize actions initiated in prior years.
Adjustments in the year ended December 31, 2023 primarily include $6.7 million of costs related to the discontinuation of a product line leading to an impairment of the associated fixed assets, inventory and intangible assets, $2.4 million related to programs to centralize and consolidate operations and professional services in Europe, $1.9 million of costs associated with the relocation of the corporate headquarters, $1.2 million separation costs associated with the 2022 cost reduction program and $0.8 million of costs associated with integration costs from prior acquisitions.
|
|||||||
(d) |
Adjustments in the last twelve months ended September 28, 2024 are primarily driven by a $1.6 million non-cash increase in cost of goods sold resulting from the fair value inventory step-up adjustment recognized as part of the purchase accounting for the acquisition of the ChlorKing business, $0.5 million of costs incurred related to litigation, partially offset by $0.5 million of gains on the sale of assets.
Adjustments in the year ended December 31, 2023 primarily include $1.8 million related to inventory and fixed asset write-offs in Europe and $1.5 million of costs incurred related to the selling stockholder offerings of shares in March, May and August 2023, which are reported in SG&A in our consolidated statements of operations.
|
|||||||
(e) | Items for the last twelve months ended September 28, 2024 are calculated by adding the items for the nine months ended September 28, 2024 plus fiscal year ended December 31, 2023 and subtracting the items for the nine months ended September 30, 2023. |
(Dollars in thousands) | Three Months Ended | Nine Months Ended | ||||||||||||||||||||||||
September 28, 2024 | September 30, 2023 | September 28, 2024 | September 30, 2023 | |||||||||||||||||||||||
Net income | $ | 16,501 | $ | 11,788 | $ | 63,922 | $ | 49,651 | ||||||||||||||||||
Tax adjustments (a) |
(451) | (4,401) | (2,203) | (2,905) | ||||||||||||||||||||||
Other adjustments and amortization: | ||||||||||||||||||||||||||
Stock-based compensation (b) |
136 | 269 | 556 | 1,001 | ||||||||||||||||||||||
Currency exchange items (c) |
(344) | 145 | (470) | 1,276 | ||||||||||||||||||||||
Acquisition and restructuring related expense, net (d) |
1,145 | 3,348 | 2,488 | 6,220 | ||||||||||||||||||||||
Other (e) |
1,920 | 2,784 | 1,657 | 4,367 | ||||||||||||||||||||||
Total other adjustments | 2,857 | 6,546 | 4,231 | 12,864 | ||||||||||||||||||||||
Loss on debt extinguishment |
— | — | 4,926 | — | ||||||||||||||||||||||
Amortization | 9,253 | 9,260 | 26,299 | 27,803 | ||||||||||||||||||||||
Tax effect (f) |
(2,815) | (3,554) | (8,360) | (9,838) | ||||||||||||||||||||||
Adjusted net income | $ | 25,345 | $ | 19,639 | $ | 88,815 | $ | 77,575 | ||||||||||||||||||
Weighted average number of common shares outstanding, basic | 215,231,886 | 213,416,502 | 214,836,643 | 212,933,763 | ||||||||||||||||||||||
Weighted average number of common shares outstanding, diluted | 221,436,206 | 220,863,228 | 221,251,355 | 220,634,232 | ||||||||||||||||||||||
Basic EPS | $ | 0.08 | $ | 0.06 | $ | 0.30 | $ | 0.23 | ||||||||||||||||||
Diluted EPS | $ | 0.07 | $ | 0.05 | $ | 0.29 | $ | 0.23 | ||||||||||||||||||
Adjusted basic EPS | $ | 0.12 | $ | 0.09 | $ | 0.41 | $ | 0.36 | ||||||||||||||||||
Adjusted diluted EPS | $ | 0.11 | $ | 0.09 | $ | 0.40 | $ | 0.35 |
(a) | Tax adjustments for the three and nine months ended September 28, 2024 reflect a normalized tax rate of 23.2% and 22.5%, respectively, compared to the Company’s effective tax rate of 21.1% and 20.9%, respectively. The Company’s effective tax rate for the three months ended September 28, 2024 primarily includes the tax benefits resulting from stock compensation and the nine months ended September 28, 2024 additionally includes a tax benefit resulting from a return-to-provision adjustment. Tax adjustments for the three and nine months ended September 30, 2023 reflect a normalized tax rate of 22.5% and 24.2%, respectively, compared to the Company's effective tax rate of (23.7)% and 19.9%, respectively. The Company’s effective tax rate for the three months ended September 30, 2023 includes the tax benefits resulting from the exercise of stock options, the release of the valuation allowance against foreign tax credit carryovers and prior-period return-to-provision adjustments, while the nine months ended rate includes the aforementioned items, partially offset by the impact of a discrete tax expense related to a change in the indefinite reinvestment assertion for one jurisdiction. |
|||||||
(b) | Represents non-cash stock-based compensation expense related to equity awards issued to management, employees, and directors. The adjustment includes only expense related to awards issued under the 2017 Equity Incentive Plan, which were awards granted prior to the effective date of the IPO. |
|||||||
(c) | Represents unrealized non-cash (gains) losses on foreign denominated monetary assets and liabilities and foreign currency contracts. |
|||||||
(d) | Adjustments in the three months ended September 28, 2024 are primarily driven by $0.7 million of transaction and integration costs associated with the acquisition of the ChlorKing business and $0.4 million of costs to finalize actions initiated in prior years. Adjustments in the three months ended September 30, 2023 are primarily driven by $1.9 million of separation costs associated with the centralization and consolidation of operations in Europe and $1.5 million of costs associated with the relocation of the corporate headquarters. Adjustments in the nine months ended September 28, 2024 are primarily driven by $1.3 million of transaction and integration costs associated with the acquisition of ChlorKing, $0.7 million of separation and other costs associated with the centralization and consolidation of operations in Europe and $0.4 million of costs to finalize actions initiated in prior years. Adjustments in the nine months ended September 30, 2023 are primarily driven by $2.1 million of costs associated with the relocation of the corporate headquarters, $1.9 million of separation costs associated with the centralization and consolidation of operations in Europe, $1.3 million of separation costs associated with the enterprise cost-reduction program initiated in 2022 and $0.8 million of integration costs from prior acquisitions. |
|||||||
(e) | Adjustments in the three months ended September 28, 2024 are primarily driven by a $1.6 million non-cash increase in cost of goods sold resulting from the fair value inventory step-up adjustment recognized as part of the purchase accounting for the acquisition of the ChlorKing business and $0.3 million of costs incurred related to litigation. Adjustments in the three months ended September 30, 2023 primarily include $1.9 million of costs related to inventory and fixed assets as part of the centralization and consolidation of operations in Europe and $0.8 million of costs incurred related to the selling stockholder offerings of shares during 2023, which are reported in SG&A in the unaudited condensed consolidated statement of operations Adjustments in the nine months ended September 28, 2024 are primarily driven by a $1.6 million non-cash increase in cost of goods sold resulting from the fair value inventory step-up adjustment recognized as part of the purchase accounting for the acquisition of the ChlorKing business and $0.5 million of costs incurred related to litigation, partially offset by $0.5 million of gains on the sale of assets. Adjustments in the nine months ended September 30, 2023 primarily includes $1.9 million of costs related to inventory and fixed assets as part of the centralization of operations in Europe, $1.5 million of costs associated with follow-on equity offerings, $0.4 million of transitional expenses incurred to enable go-forward public company regulatory compliance and other miscellaneous items the Company believes are not representative of its ongoing business operations. |
|||||||
(f) | The tax effect represents the immediately preceding adjustments at the normalized tax rates as discussed in footnote (a) above. | |||||||
(Dollars in thousands) | Three Months Ended | Three Months Ended | ||||||||||||||||||||||||
September 28, 2024 | September 30, 2023 | |||||||||||||||||||||||||
NAM | E&RW | NAM | E&RW | |||||||||||||||||||||||
Net sales | $ | 194,968 | $ | 32,601 | $ | 185,070 | $ | 35,234 | ||||||||||||||||||
Gross profit | $ | 101,877 | $ | 11,218 | $ | 91,456 | $ | 13,955 | ||||||||||||||||||
Gross profit margin % | 52.3 | % | 34.4 | % | 49.4 | % | 39.6 | % | ||||||||||||||||||
Segment income | $ | 51,569 | $ | 2,475 | $ | 40,108 | $ | 6,413 | ||||||||||||||||||
Depreciation | $ | 4,404 | $ | 271 | $ | 4,027 | $ | 246 | ||||||||||||||||||
Amortization | 1,677 | — | 1,738 | — | ||||||||||||||||||||||
Stock-based compensation | 107 | — | 75 | 11 | ||||||||||||||||||||||
Other (a) |
1,704 | — | 115 | — | ||||||||||||||||||||||
Total adjustments | 7,892 | 271 | 5,955 | 257 | ||||||||||||||||||||||
Adjusted segment income | $ | 59,461 | $ | 2,746 | $ | 46,063 | $ | 6,670 | ||||||||||||||||||
Segment income margin % | 26.4 | % | 7.6 | % | 21.7 | % | 18.2 | % | ||||||||||||||||||
Adjusted segment income margin % | 30.5 | % | 8.4 | % | 24.9 | % | 18.9 | % | ||||||||||||||||||
(a) | The three months ended September 28, 2024 primarily includes a $1.6 million non-cash increase in cost of goods sold resulting from the fair value inventory step-up adjustment recognized as part of the purchase accounting for the acquisition of the ChlorKing business. The three months ended September 30, 2023 includes miscellaneous items the Company believes are not representative of its ongoing business operations. |
|||||||
(Dollars in thousands) | Nine Months Ended | Nine Months Ended | ||||||||||||||||||||||||
September 28, 2024 | September 30, 2023 | |||||||||||||||||||||||||
NAM | E&RW | NAM | E&RW | |||||||||||||||||||||||
Net sales | $ | 609,510 | $ | 115,021 | $ | 585,126 | $ | 128,857 | ||||||||||||||||||
Gross profit | $ | 319,184 | $ | 43,577 | $ | 288,911 | $ | 50,901 | ||||||||||||||||||
Gross profit margin % | 52.4 | % | 37.9 | % | 49.4 | % | 39.5 | % | ||||||||||||||||||
Segment income | $ | 166,646 | $ | 16,800 | $ | 144,346 | $ | 25,647 | ||||||||||||||||||
Depreciation | $ | 12,619 | $ | 791 | $ | 11,952 | $ | 694 | ||||||||||||||||||
Amortization | 4,874 | — | 5,026 | — | ||||||||||||||||||||||
Stock-based compensation | 176 | 10 | 417 | 34 | ||||||||||||||||||||||
Other (a) |
1,723 | — | 503 | — | ||||||||||||||||||||||
Total adjustments | 19,392 | 801 | 17,898 | 728 | ||||||||||||||||||||||
Adjusted segment income |
$ | 186,038 | $ | 17,601 | $ | 162,244 | $ | 26,375 | ||||||||||||||||||
Segment income margin % | 27.3 | % | 14.6 | % | 24.7 | % | 19.9 | % | ||||||||||||||||||
Adjusted segment income margin % |
30.5 | % | 15.3 | % | 27.7 | % | 20.5 | % |
(a) | The nine months ended September 28, 2024 primarily includes a $1.6 million non-cash increase in cost of goods sold resulting from the fair value inventory step-up adjustment recognized as part of the purchase accounting for the acquisition of the ChlorKing business. The nine months ended September 30, 2023 includes miscellaneous items the Company believes are not representative of its ongoing business operations. |
|||||||